CN111205346B - Oleanolic acid derivative and medical application thereof - Google Patents

Oleanolic acid derivative and medical application thereof Download PDF

Info

Publication number
CN111205346B
CN111205346B CN202010084760.0A CN202010084760A CN111205346B CN 111205346 B CN111205346 B CN 111205346B CN 202010084760 A CN202010084760 A CN 202010084760A CN 111205346 B CN111205346 B CN 111205346B
Authority
CN
China
Prior art keywords
disease
ampk
acid
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010084760.0A
Other languages
Chinese (zh)
Other versions
CN111205346A (en
Inventor
孙宏斌
程亚龙
温小安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN202010084760.0A priority Critical patent/CN111205346B/en
Publication of CN111205346A publication Critical patent/CN111205346A/en
Application granted granted Critical
Publication of CN111205346B publication Critical patent/CN111205346B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The invention discloses a novel pentacyclic triterpenoid AMPK agonist oleanolic acid derivative and a medical application thereof, in particular to a compound shown as a formula I or a formula II or a pharmaceutically acceptable salt, ester or solvate thereof, which can be used for preparing an AMPK agonist with activity of enhancing AMPK phosphorylation level and a medicine for preventing or treating AMPK mediated diseases. The novel pentacyclic triterpenoid has obvious AMPK agonistic activity, and the activity of the novel pentacyclic triterpenoid is obviously superior to that of a recognized AMPK agonistAICAR has better pharmacokinetic properties such as oral bioavailability and the like and very good safety.

Description

Oleanolic acid derivative and medical application thereof
Technical Field
The invention relates to the field of biomedicine, relates to a novel pentacyclic triterpenoid compound with AMPK agonistic activity, and particularly relates to an oleanolic acid derivative and medical application thereof, and also relates to application of the compound in preparing a medicine for preventing or treating AMPK-mediated diseases and a pharmaceutical composition of the compound.
Background
AMPK (adenylate activated protein kinase) is a key kinase for regulating and controlling body energy metabolism and inflammatory reaction, and phosphorylation activation of AMPK can overcome insulin resistance, reduce blood sugar, reduce blood fat (by inhibiting synthesis of fatty acid and cholesterol), resist inflammation, apoptosis, fibrosis, promote mitochondrial synthesis, enhance oxidative metabolism of mitochondria, resist aging, and resist tumors (physiol. rev.2009,89,1025). In recent years, the anti-inflammatory and anti-fibrotic effects of AMPK have been receiving increasing attention (Nature 2013,493,346), and a possible mechanism thereof is that AMPK exerts anti-inflammatory and anti-fibrotic effects by enhancing the transcriptional function of estrogen-related receptor α (ERR α) (Immunity 2015,43, 80).
There is increasing evidence that AMPK dysfunction is closely associated with the development and progression of a variety of diseases. AMPK-mediated diseases include metabolic diseases and cardiovascular and cerebrovascular diseases such as insulin resistance, metabolic syndrome, type 1 or type 2 diabetes mellitus, hyperlipidemia, obesity, atherosclerosis, myocardial ischemia, myocardial infarction, arrhythmia, coronary heart disease, hypertension, heart failure, myocardial hypertrophy, myocarditis, diabetic complications (including diabetic cardiomyopathy, diabetic nephropathy, retinopathy, neuropathy, diabetic ulcer and the like), non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcoholic fatty liver, liver cirrhosis, gout, stroke, cerebral infarction and the like; AMPK-mediated diseases also include inflammatory diseases, autoimmune diseases, organ fibrotic diseases, nerve injury diseases or secondary diseases caused by infection with pathogens, such as pneumonia, asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, bronchiolitis obliterans, idiopathic pulmonary fibrosis, cystic fibrosis lung diseases, allergic rhinitis, inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis), polycystic kidney disease, polycystic ovary syndrome (PCOS), Behcet's disease, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis, osteoarthritis, synovitis, tendonitis, thromboangiitis obliterans, phlebitis, intermittent claudication, keloid, psoriasis, ichthyosis, bullous pemphigoid, dermatitis, contact dermatitis, pancreatitis, chronic nephritis, cystitis, meningitis, gastritis, septicemia, pyoderma gangrenosum, psoriasis, chronic nephritis, cystitis, meningitis, and other diseases, Uveitis, Parkinson's disease, Alzheimer's disease, alpha-synucleinopathy, depression, multiple sclerosis, amyotrophic lateral sclerosis, fibromyalgia syndrome, neuralgia, Down's syndrome, Hallervorden-Spatkis disease, Huntington's chorea or Wilson's disease, etc.
AMPK agonists have been reported in the literature to prevent and treat a variety of AMPK-mediated diseases (j.med. chem.,2015,582; Nature 2013,493,346; Experimental Neurology 2017,298, 31; Biochemical Pharmacology 2010,80, 1708; Current Drug Targets,2016,17, 908; Nat Rev Drug Discov,2019, DOI:10.1038/s 41573-019-. For example, metformin, a hypoglycemic agent widely used clinically, is thought to exert various clinical effects mainly by activating AMPK (j.clin.invest.2001,108, 1167). Despite the wide clinical potential of AMPK agonists, however, substantial progress has not been made to develop novel, safe and effective AMPK agonists to date. For reasons of safety or efficacy, AMPK agonists under investigation have entered the clinical study stage for a very limited number of reasons. For example, the broad spectrum AMPK-beta subunit agonist MK-8722, although lowering blood glucose, was found to have irreversible cardiac hypertrophy side effects in the animal heart in rat and monkey experiments (Science 2017,357,507). In addition, AICAR, one of the most commonly used AMPK agonists (Eur. J. biochem.1995,229,558), has also been terminated in clinical trials due to its large toxic side effects (J Clin Pharmacol 1991,31: 342-347).
In conclusion, the development of novel AMPK agonists with high activity and low toxic and side effects is urgently needed in clinic. On the other hand, oleanolic acid is a pentacyclic triterpene commonly found in medicinal plants, which has a wide range of biological activities (Nat Prod Rep 2011,28, 543). The method has great significance in the field of biological medicine for researching pentacyclic triterpenoid derivatives with stronger activity and novel structures, such as oleanolic acid derivatives.
Disclosure of Invention
The purpose of the invention is as follows: aiming at the problems in the prior art in the field of AMPK agonist development, the invention provides a novel oleanolic acid derivative; the novel oleanolic acid derivative provided by the invention is a novel AMPK agonist, so that the novel oleanolic acid derivative can be used for preparing a medicine for preventing or treating AMPK-mediated diseases.
The invention unexpectedly discovers a series of potent novel AMPK agonists when the structure of the oleanolic acid is modified, and the AMPK agonistic activity of the novel AMPK agonists is obviously superior to that of the accepted AICAR which is an AMPK agonist.
The technical scheme is as follows: in order to achieve the above objects, the oleanolic acid derivatives represented by the following formula I or formula II or pharmaceutically acceptable salts or esters or solvates thereof according to the present invention:
Figure BDA0002381652130000021
wherein the content of the first and second substances,
r is H,
Figure BDA0002381652130000022
RaCO-or PO3H2；
R1Is H, C1-C5C substituted by alkyl or by substituent Y1-C5Alkyl, the substituent Y is OH, C (O) NH2、NH2、NHC(O)CH3Pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, morpholin-4-yl, thiomorpholin-1, 1-dioxo-4-yl, N-dimethylamino, N-diethylamino, trimethylammonium, or diethanolamino;
Rac unsubstituted or substituted by substituents L1-C5Alkyl, said substituent L being one or two substituents independently selected from the group consisting of: OH, C (O) OH, NH2Pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, morpholin-4-yl, thiomorpholin-1, 1-dioxo-4-yl or NHC (O) CH (CH)3)NHC(O)CH(CH3)NH。
In certain preferred embodiments, the compound, or a pharmaceutically acceptable salt or ester or solvate thereof, is selected from the group consisting of:
Figure BDA0002381652130000031
Figure BDA0002381652130000041
Figure BDA0002381652130000051
Figure BDA0002381652130000061
Figure BDA0002381652130000071
the compounds of the present invention may also be used as pharmaceutically acceptable salts. The salt may be an acid salt of at least one of the following acids: galactaric acid, D-glucuronic acid, glycerophosphoric acid, hippuric acid, isethionic acid, lactobionic acid, maleic acid, 1, 5-naphthalenedisulfonic acid, naphthalene-2-sulfonic acid, pivalic acid, terephthalic acid, thiocyanic acid, cholic acid, n-dodecylsulfuric acid, benzenesulfonic acid, citric acid, D-glucose, glycolic acid, lactic acid, malic acid, malonic acid, mandelic acid, phosphoric acid, propionic acid, hydrochloric acid, sulfuric acid, tartaric acid, succinic acid, formic acid, hydroiodic acid, hydrobromic acid, methanesulfonic acid, nicotinic acid, nitric acid, orotic acid, oxalic acid, picric acid, L-pyroglutamic acid, saccharinic acid, salicylic acid, gentisic acid, p-toluenesulfonic acid, valeric acid, palmitic acid, sebacic acid, stearic acid, lauric acid, acetic acid, adipic acid, carbonic acid, benzenesulfonic acid, ethanedisulfonic acid, ethylsuccinic acid, fumaric acid, 3-hydroxynaphthalene-2-carboxylic acid, 1-hydroxynaphthalene-2-carboxylic acid, oleic acid, undecylenic acid, ascorbic acid, camphoric acid, camphorsulfonic acid, dichloroacetic acid, ethanesulfonic acid. Alternatively, the salt may be a salt of a compound of the present invention with a metal ion (including sodium, potassium, calcium, etc.) or a pharmaceutically acceptable amine (including ethylenediamine, tromethamine, etc.), an ammonium ion or choline. The compounds of the present invention may also be comprised in pharmaceutical compositions in the form of esters, prodrugs, N-oxides or solvates thereof.
The invention provides application of the compound shown in the formula I or the formula II or pharmaceutically acceptable salt, ester or solvate thereof in preparing AMPK agonist with AMPK phosphorylation level enhancing activity. The compounds of the present invention have significant agonistic activity against AMPK, and thus may be used to prepare AMPK agonists having activity of enhancing phosphorylation level of AMPK.
The invention also provides application of the compound shown in the formula I or the formula II or pharmaceutically acceptable salt, ester or solvate thereof in preparing a medicament for preventing or treating AMPK mediated diseases.
Wherein the AMPK-mediated disease comprises a metabolic disease, a cardiovascular disease, a cerebrovascular disease, an inflammatory disease, an autoimmune disease, an organ fibrosis disease, a neurodegenerative disease, a secondary disease caused by pathogen infection, a mitochondrial dysfunction or disorder disease or a tumor.
The AMPK mediated diseases, such as metabolic diseases and cardiovascular and cerebrovascular diseases, comprise: such as insulin resistance, metabolic syndrome, type 1 or type 2 diabetes, hyperlipidemia, obesity, atherosclerosis, myocardial ischemia, myocardial infarction, arrhythmia, coronary heart disease, hypertension, heart failure, myocardial hypertrophy, myocarditis, diabetic complications (including diabetic cardiomyopathy, diabetic nephropathy, retinopathy, neuropathy, diabetic ulcer and the like), non-alcoholic fatty liver, non-alcoholic steatohepatitis, alcoholic fatty liver, liver cirrhosis, gout, stroke or cerebral infarction and the like.
The AMPK-mediated diseases, such as inflammatory diseases, autoimmune diseases, organ fibrosis diseases, nerve injury diseases or secondary diseases caused by infection with pathogens, include: pneumonia, asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, bronchiolitis obliterans, idiopathic pulmonary fibrosis, cystic fibrosis lung disease, allergic rhinitis, inflammatory bowel disease (such as crohn's disease and ulcerative colitis), polycystic kidney disease, polycystic ovary syndrome (PCOS), behcet's disease, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis, osteoarthritis, synovitis, tendonitis, thromboangiitis obliterans, phlebitis, intermittent claudication, keloid, psoriasis, ichthyosis, bullous pemphigoid, dermatitis, contact dermatitis, pancreatitis, chronic nephritis, cystitis, meningitis, gastritis, septicemia, pyoderma gangrenosum, uveitis, parkinson's disease, alzheimer's disease, alpha-synucleinopathy, depression, multiple sclerosis, amyotrophic lateral sclerosis, fibromyalgia syndrome, Neuralgia, Down's syndrome, Harlervorden-Spatz disease, Huntington's chorea or Wilson's disease, etc.
Such AMPK-mediated diseases, such as mitochondrial dysfunction and disorder diseases, include: myasthenia, myoclonus, exercise intolerance, cahns-seire syndrome, chronic fatigue syndrome, li's syndrome, mitochondrial myopathy-encephalopathy-hyperlactacidemia, stroke syndrome, or stroke-like episodes. Likewise, the compounds of the invention may also be useful in the treatment of muscular dystrophy states, for example, duchenne muscular dystrophy, conchal muscular dystrophy or friedrich's ataxia.
Such AMPK-mediated diseases, such as tumors, include: bone cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disease, multiple myeloma, myelodysplastic syndrome, hodgkin's lymphoma, non-hodgkin's lymphoma, hemangioma, granuloma, xanthoma, meningiosarcoma, glioma, astrocytoma, medulloblastoma, ependymoma, germ cell tumor (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, fibroma, sarcoma, esophageal cancer, gastric cancer, pancreatic cancer, colorectal cancer, colon cancer, rectal cancer, renal cancer, prostate cancer, lymphatic cancer, testicular cancer, interstitial cell cancer, lung cancer, liver cancer, skin cancer, malignant melanoma, basal cell carcinoma, and the like.
The invention relates to a pharmaceutical composition with AMPK phosphorylation level enhancing activity, which comprises a therapeutically effective amount of a compound shown in formula I or formula II or a pharmaceutically acceptable salt, ester or solvate thereof serving as an active ingredient and a pharmaceutically acceptable auxiliary material.
The invention relates to a pharmaceutical composition for preventing or treating AMPK-mediated diseases, which comprises a therapeutically effective amount of a compound shown in formula I or formula II or a pharmaceutically acceptable salt, ester or solvate thereof serving as an active ingredient and a pharmaceutically acceptable auxiliary material.
The above-mentioned adjuvants which can be arbitrarily mixed may be changed depending on the dosage form, administration form and the like. Examples of the auxiliary materials include excipients, binders, disintegrating agents, lubricants, flavoring agents, coloring agents, sweetening agents, and the like. The pharmaceutical composition can be in the form of capsules, powders, tablets, granules, pills, injections, syrups, oral liquids, inhalants, ointments, suppositories or patches and other pharmaceutically conventional preparations.
If desired, the compounds of formula I or formula II or pharmaceutically acceptable salts or esters or solvates thereof of the present invention may be used in combination with one or more other types of agents for the prophylaxis or treatment of AMPK-mediated diseases, including but not limited to the following combinations.
The drug optionally used in combination with the compound of the present invention may be one or more antidiabetic drugs including metformin, sulfonylurea hypoglycemic agents (e.g., glyburide and glimepiride, etc.), glucosidase inhibitors (e.g., acarbose and miglitol, etc.), PPAR γ agonists (e.g., pioglitazone and rosiglitazone), PPAR α/γ dual agonists, dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin, saxagliptin, alogliptin and linagliptin, etc.), glinide hypoglycemic agents (e.g., repaglinide and nateglinide, etc.), SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, engagliflozin, eggliflozin, and troglifloxagliflozin, etc.), glucokinase agonists (e.g., HMS5552, etc.), insulin, glucagon-like peptide-1 (GLP-1) class drugs (e.g., exenatide, gliflozin, and gliflozin, etc.) Liraglutide, lissamide, dolabrupeptide, benalotide, and albiglutide, etc.), a PTP1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, an AMPK agonist, a GPR40 agonist, or a GPR120 agonist.
The drug optionally used in combination with the compound of the present invention may be one or more of anti-obesity drugs including lorcaserin, orlistat and glucagon-like peptide-1 (GLP-1) drugs (e.g., exenatide, liraglutide, dolabrupeptide, benalolutide, and abiglutide, etc.), and the like.
The drug selected for use in combination with the compounds of the present invention may be one or more anti-non-alcoholic fatty liver disease drugs, including: AMPK agonists (e.g., metformin), Farnesoid X Receptor (FXR) agonists (e.g., obeticholic acid, GS-9674, EDP-305 and LJN452, etc.), acetyl-CoA carboxylase (ACC) inhibitors (e.g., GS-0976, etc.), apoptosis signal-regulating kinase-1 (ASK1) inhibitors (e.g., Selosertib, etc.), PPAR agonists (e.g., Elafibranor, Saroglitazar, IVA337 and MSDC-0602K, etc.), caspase inhibitors (e.g., Emricasan, etc.), stearoyl-CoA desaturase 1(SCD1) inhibitors (e.g., Aramchol, etc.), long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., Semaglutide, etc.), apical sodium-dependent bile salt transporter (ASBT) inhibitors (e.g., Volixibat, etc.), vascular adhesion protein 1(VAP-1) inhibitors (e.g., BI 1467335, etc.), CCR5R blockers (e.g., Cenicriviroc, etc.), and thyroid hormone receptor beta (THR-beta) agonists (e.g., MGL-3196, etc.), among others.
The drug which can be optionally used in combination with the compound of the present invention may be one or more hypolipidemic drugs, including nicotinic acid, statins (e.g., lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin and pitavastatin), cholesterol absorption inhibitors (e.g., ezetimibe, etc.), fibrates (e.g., clofibrate, bezafibrate, fenofibrate, etc.), PCSK9 inhibitors (e.g., evorocumab, Alirocumab, etc.), CETP inhibitors (e.g., anacetrapib, etc.), AMPK agonists and ACC inhibitors (e.g., GS-0976, etc.), and the like.
The amount of the compound of formula I or formula II of the present invention or a pharmaceutically acceptable salt or ester or solvate thereof may be appropriately changed depending on the age, body weight, symptoms and administration route of the patient, etc. When administered to an adult (about 60kg), the compound of formula I or formula II or a pharmaceutically acceptable salt or ester or solvate thereof is administered in an amount of 1mg to 1000mg, preferably 5mg to 500mg, more preferably 10mg to 60mg per time, 1 to 3 times per day. This dosage range may also vary depending on the degree of disease and dosage form.
Oleanolic acid used in the present invention can be commercially available. The synthesis of oleanolic acid derivatives can be carried out by referring to the methods of examples or modified methods.
Has the advantages that: compared with the prior art, the invention has the following advantages:
(1) the novel oleanolic acid derivative has strong AMPK agonistic activity, and the activity of the novel oleanolic acid derivative is obviously superior to that of a recognized AMPK agonist AICAR.
(2) Compared with the lead compound oleanolic acid, the novel pentacyclic triterpenoid compound has better pharmacokinetic properties such as oral bioavailability and the like.
(3) Compared with the existing AMPK agonist AICAR (clinical test is stopped due to large toxic and side effects) and MK-8722 (side effects of irreversible cardiac hypertrophy can be caused), the novel pentacyclic triterpenoid compound has very good safety.
(4) The novel oleanolic acid derivative serving as the AMPK agonist has the advantages of low cost, easiness in preparation, small potential side effect and the like compared with the existing AMPK agonist, can be used independently, can also be used together with one or more other types of drugs for preventing or treating AMPK-mediated diseases, and is expected to become a novel drug for preventing or treating AMPK-mediated diseases.
Drawings
FIG. 1 is a single crystal diffractogram of Compound B-1 in the example;
FIG. 2 is a graph of AMPK agonistic activity of some compounds on Huh-7 cells (Western Blot assay).
Detailed Description
The present invention will be described in detail with reference to examples. In the present invention, the following examples are given for better illustration of the present invention and are not intended to limit the scope of the present invention. Various changes and modifications may be made to the invention without departing from the spirit and scope of the invention.
Example 1
12-ene-3 beta-acetoxy-28- (oxazolin-2-yl) -oleanane (Compound A-2)
Figure BDA0002381652130000111
Oleanolic acid (OA, 10g, 21.9mmol) was dissolved in pyridine (150mL), 4-dimethylaminopyridine (0.26g, 2.19mmol) was added, acetic anhydride (8.3mL, 87.6mmol) was added slowly, and the mixture was stirred at room temperature overnight. After completion of the reaction, 1N hydrochloric acid (300mL) was added, and extraction was performed with ethyl acetate (300mL × 3), and the mixture was washed with saturated brine (300mL × 3), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and filtered with suction (petroleum ether: dichloromethane 50: 1) to obtain compound I-1 (white solid, 8.2g, yield 75%).
Compound I-1(5g, 10mmol) was dissolved in anhydrous dichloromethane (80mL), and oxalyl chloride (1.7mL, 20mmol) and N, N-dimethylformamide (5 drops) were slowly added dropwise with stirring and reacted at room temperature for 5 hours. After completion of the TLC detection reaction, the solvent was distilled off under reduced pressure to obtain Compound I-2 (yellow solid, 5.17g, yield 100%).
Compound I-2(5.17g, 10mmol) was dissolved in anhydrous dichloromethane (80mL), 2-bromoethylamine hydrobromide (4g, 20mmol) was added, triethylamine (5.5mL, 40mmol) was dissolved in anhydrous dichloromethane (20mL), and the triethylamine solution in dichloromethane was slowly added dropwise to the reaction using a constant pressure dropping funnel. Stir at room temperature overnight. After completion of the TLC detection reaction, the solvent was distilled off under reduced pressure, water (300mL) was added and extracted with ethyl acetate (300 mL. times.3), and the mixture was washed with saturated brine (300 mL. times.3), and the filtrate was concentrated and dried to obtain a crude compound I-3 which was used as it was in the next reaction.
The crude compound I-3 obtained in the previous step was dissolved in N, N-dimethylformamide (100mL), and potassium carbonate (2.7g, 20mml) was added thereto, followed by reaction with heating at 50 ℃ for 12 hours. After the reaction is finished, pouring the reaction liquid into 500mL of ice water, separating out white solid, carrying out suction filtration, and drying a filter cake. Subjecting to silica gel column chromatography (petroleum ether: acetic acid)Ethyl ester 10:1) purification afforded compound a-2 (white solid, 3.76g, two step yield 72%):1H NMR(300MHz,CDCl3)δ5.40-5.16(m,1H),4.62-4.37(m,1H),4.23-4.02(m,2H),3.91-3.66(m,2H),2.94-2.78(m,1H),2.04(s,3H),1.13(s,3H),0.93(s,6H),0.90(s,3H),0.86(s,3H),0.86(s,3H),0.76(s,3H).ESI-MS:m/z 524.5[M+H]+。
example 2
Olean-12-en-28- (oxazolin-2-yl) -3 beta-ol
Figure BDA0002381652130000121
Compound A-2(3.5g, 6.6mmol) was dissolved in 50mL of methanol, potassium hydroxide (3.7g, 66mmol) was added, and the reaction was heated to 50 ℃ and checked for completion by TLC. After completion of the reaction, it was cooled to room temperature, 50mL of water was added, extraction was performed with ethyl acetate (50mL × 3), and the mixture was washed with saturated brine (50mL × 3), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (petroleum ether: ethyl acetate ═ 10:1) to obtain compound a-1 (white solid, 3.0g, yield 95%):1H NMR(300MHz,DMSO)δ5.36-5.18(m,1H),4.26-4.03(m,2H),3.88-3.63(m,2H),3.27-3.15(m,1H),2.93-2.77(m,1H),1.13(s,3H),0.99(s,3H),0.94(s,3H),0.90(s,6H),0.78(s,3H),0.76(s,3H).ESI-MS:m/z 482.4[M+H]+。
example 3
12-ene-3 beta-propionyloxy-28- (oxazoline-2-yl) -oleanane (compound A-3)
Figure BDA0002381652130000131
Compound a-1(200mg, 0.4mmol) was dissolved in pyridine (3mL), 4-dimethylaminopyridine (5mg, 0.04mmol) and propionic anhydride (133uL, 1mmol) were sequentially added, the reaction was stirred at room temperature, 1N hydrochloric acid (5mL) was added after completion of the reaction by TLC detection, extraction was performed with ethyl acetate (5mL × 3), washing was performed with saturated saline (5mL × 3), drying was performed with anhydrous sodium sulfate, concentration was performed under reduced pressure, and chromatography was performed with a silica gel column (petroleum ether: ethyl acetate ═ 10:1),compound A-3 (white solid, 178mg, 80% yield) was obtained:1H NMR(300MHz,CDCl3)δ5.32-5.20(m,1H),4.58-4.42(m,1H),4.22-4.03(m,2H),3.91-3.71(m,2H),2.94-2.79(m,1H),2.32(q,J＝7.6Hz,2H),0.93(s,6H),0.90(s,3H),0.86(s,9H),0.76(s,3H).ESI-MS:m/z 538.5[M+H]+。
example 4
12-ene-3 beta-butyryloxy-28- (oxazoline-2-yl) -oleanane (compound A-4)
Figure BDA0002381652130000141
Referring to the procedure of example 3, substituting propionic anhydride for succinic anhydride produced compound a-4:1H NMR(300MHz,CDCl3)δ5.32-5.22(m,1H),4.55-4.42(m,1H),4.21-4.09(m,2H),3.91-3.68(m,2H),2.94-2.78(m,1H),2.28(t,J＝7.4Hz,2H),1.13(s,2H),0.93(s,4H),0.90(s,2H),0.86(s,3H),0.76(s,2H).ESI-MS:m/z 552.5[M+H]+。
example 5
12-ene-3 beta-pentanoyloxy-28- (oxazoline-2-yl) -oleanane (compound A-5)
Figure BDA0002381652130000142
Referring to the procedure of example 3, substituting propionic anhydride for pentanoic anhydride, compound a-5 is prepared:1H NMR(300MHz,CDCl3)δ5.31-5.22(m,1H),4.54-4.42(m,1H),4.21-4.06(m,2H),3.85-3.68(m,2H),2.90-2.82(m,1H),2.29(t,J＝7.5Hz,2H),0.93(s,6H),0.91(s,3H),0.90(s,3H),0.86(s,6H),0.76(s,3H).ESI-MS:m/z 566.5[M+H]+。
example 6
12-en-3 β - (4-fluorobenzoyl) oxy-28- (oxazolin-2-yl) -oleanane (compound A-6)
Figure BDA0002381652130000143
Compound A-1(200mg, 0.4mmol) was dissolved in dichloromethane (3mL), N' -dicyclohexylcarbodiimide (247mg, 1.2mmol), 4-dimethylaminopyridine (48mg, 0.4mmol) and p-fluorobenzoic acid (122. mu.L, 1mmol) were added in this order, and the reaction was stirred at room temperature. TLC detection after completion of the reaction was washed with water (5mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether: ethyl acetate ═ 10:1) to give compound a-6 (white solid, 188mg, yield 78%):1H NMR(300MHz,CDCl3)δ8.05(dd,J＝8.4,5.7Hz,2H),7.10(t,J＝8.6Hz,2H),5.32-5.22(m,1H),4.82-4.64(m,1H),4.24-4.04(m,2H),3.91-3.64(m,2H),2.95-2.77(m,1H),1.00(s,3H),0.98(s,3H),0.94(s,6H),0.91(s,3H),0.78(s,3H).ESI-MS:m/z 604.5[M+H]+。
example 7
12-ene-3 beta- (4-chlorobenzoyl) oxy-28- (oxazolin-2-yl) -oleanane (Compound A-7)
Figure BDA0002381652130000151
Referring to the procedure of example 6, p-fluorobenzoic acid was substituted for p-chlorobenzoic acid to give compound a-7:1H NMR(300MHz,CDCl3)δ7.97(d,J＝8.4Hz,2H),7.41(d,J＝8.6Hz,2H),5.48-5.39(m,1H),4.82-4.63(m,1H),3.93-3.72(m,2H),3.67-3.53(m,2H),2.64-2.48(m,1H),1.01(s,3H),0.99(s,3H),0.92(s,12H),0.81(s,3H).ESI-MS:m/z 620.4[M+H]+。
example 8
12-ene-3 beta- (4-methylbenzoyl) oxy-28- (oxazolin-2-yl) -oleanane (Compound A-8)
Figure BDA0002381652130000152
Referring to the procedure of example 6, p-fluorobenzoic acid was substituted for p-methylbenzoic acid to give compound a-8:1H NMR(300MHz,CDCl3)δ8.00(d,J＝8.1Hz,2H),7.27(d,J＝7.2Hz,2H),5.46-5.40(m,1H),4.78-4.66(m,1H),3.65-3.56(m,2H),3.43-3.26(m,2H),2.63-2.50(m,1H),2.43(s,3H),1.19(s,3H),1.01(s,3H),0.99(s,3H),0.94(s,3H),0.92(s,6H),0.81(s,3H).ESI-MS:m/z 600.4[M+H]+。
example 9
12-ene-3 beta- (4-methoxybenzoyl) oxy-28- (oxazolin-2-yl) -oleanane (Compound A-9)
Figure BDA0002381652130000161
Referring to the procedure of example 6, p-fluorobenzoic acid was substituted for p-methoxybenzoic acid to give compound a-9:1H NMR(300MHz,CDCl3)δ8.07(d,J＝8.5Hz,2H),6.95(d,J＝8.5Hz,2H),5.52-5.33(m,1H),4.78-4.60(m,1H),3.88(s,3H),3.68-3.58(m,2H),3.46-3.23(m,2H),2.64-2.48(m,1H),1.19(s,3H),1.01(s,3H),0.99(s,3H),0.92(s,9H),0.81(s,3H).ESI-MS:m/z 616.5[M+H]+。
example 10
12-ene-3 beta- (4-trifluoromethoxybenzoyl) oxy-28- (oxazolin-2-yl) -oleanane (Compound A-10)
Figure BDA0002381652130000162
Referring to the procedure of example 6, p-fluorobenzoic acid was substituted for p-trifluoromethoxybenzoic acid to give compound a-10:1H NMR(300MHz,CDCl3)δ8.10(d,J＝8.7Hz,2H),7.35(d,J＝8.5Hz,2H),5.52-5.43(m,1H),4.83-4.74(m,1H),3.69-3.43(m,2H),3.36-3.13(m,2H),2.56-2.43(m,1H),1.23(s,3H),1.03(s,3H),1.01(s,3H),0.95(s,3H),0.93(s,6H),0.81(s,3H).ESI-MS:m/z 692.8[M+Na]+。
example 11
12-ene-3 beta- (4-methoxylbenzoyl) oxy-28- (oxazolin-2-yl) -oleanane (Compound A-11)
Figure BDA0002381652130000171
Referring to the procedure of example 6, p-fluorobenzoic acid was substituted for p-methoxylbenzoic acid to give compound a-11:1H NMR(300MHz,CDCl3)δ8.26-7.96(m,4H),5.46-5.39(m,1H),4.83-4.69(m,1H),3.95(s,3H),3.66-3.56(m,2H),3.42-3.25(m,2H),2.66-2.49(m,1H),1.19(s,3H),1.03(s,3H),1.00(s,3H),0.95(s,3H),0.92(s,6H),0.81(s,3H).ESI-MS:m/z 644.4[M+H]+。
example 12
12-ene-3 beta- (3-pyridinoformyl) oxy-28- (oxazolin-2-yl) -oleanane (compound A-12)
Figure BDA0002381652130000172
Referring to the procedure of example 6, substituting p-fluorobenzoic acid for nicotinic acid gives compound a-12:1H NMR(300MHz,CDCl3)δ9.22(s,1H),8.76(d,J＝4.2Hz,1H),8.29(d,J＝7.7Hz,1H),7.44-7.33(m,1H),5.41-5.17(m,1H),4.85-4.67(m,1H),4.27-4.03(m,2H),3.90-3.62(m,2H),2.97-2.76(m,1H),1.15(s,3H),1.01(s,3H),0.98(s,3H),0.94(s,6H),0.91(s,3H),0.78(s,3H).ESI-MS:m/z 587.6[M+H]+。
example 13
12-ene-3 beta- (2-carboxybenzoyl) oxy-28- (oxazolin-2-yl) -oleanane (Compound A-13)
Figure BDA0002381652130000181
Compound A-1(200mg, 0.4mmol) was dissolved in methylene chloride (4mL), and N, N' -dicyclohexylcarbodiimide (247mg, 1.2mmol), 4-dimethylaminopyridine (48mg, 0.4mmol) and monobenzyl phthalate (205mg, 0.8mmol) were added in this order, and the reaction was stirred at room temperature. After completion of the TLC detection reaction, it was washed with water (5mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether: ethyl acetate ═ 10:1) to obtain compound I-4 (white solid, 260mg, yield 78%).
Compound I-4(200mg, 0.277mmol) was dissolved in DCM (4mL), 10% palladium on carbon (10mg) was added, and the reaction was stirred under hydrogen atmosphere at room temperature overnight. After completion of the TLC detection reaction, celite was filtered and the filtrate was concentrated to give Compound A-13 (white solid, 156mg, 90% yield):1H NMR(300MHz,CDCl3)δ7.88-7.79(m,1H),7.73-7.64(m,1H),7.59-7.47(m,2H),5.32-5.26(m,1H),4.82-4.67(m,1H),4.28-4.14(m,2H),3.96-3.69(m,2H),2.94-2.79(m,1H),1.15(s,3H),0.97(s,3H),0.94(s,3H),0.94(s,3H),0.90(s,6H),0.76(s,3H).ESI-MS:m/z630.6[M+H]+。
example 14
12-ene-3 β -phosphoxy-28- (oxazolin-2-yl) -oleanane (Compound A-14)
Figure BDA0002381652130000182
Figure BDA0002381652130000191
Dissolving compound a-1(200mg, 0.4mmol) in dichloromethane (8mL), first adding 1H-tetrazole (109 μ L, 1.2mmol), stirring at room temperature for 10 minutes, then adding dibenzyl N, N-diisopropylphosphoramidite (153 μ L, 0.45mmol), stirring at room temperature for 4 hours under nitrogen atmosphere, after TLC detection reaction is complete, adding m-chloroperoxybenzoic acid (157mg, 0.9mmol), stirring at room temperature for 4 hours, after TLC detection reaction is complete, adding saturated ammonium chloride solution (8mL), quenching, washing with saturated sodium bicarbonate solution (5mL × 2), drying over anhydrous sodium sulfate, filtering, concentrating the filtrate, and purifying by silica gel column chromatography (petroleum ether: ethyl acetate ═ 15: 1) to obtain compound I-4 (white solid, 266mg, 74% yield).
Compound I-4(200mg, 0.23mmol) was dissolved in a mixed solvent of tetrahydrofuran (2mL) and methanol (2mL), 10% palladium on carbon (10mg) was added, and the reaction was stirred under hydrogen atmosphere at room temperature overnight. After TLC detection reaction was complete, celite was filtered, the filtrate was concentrated and slurried with ethyl acetate to give compound a-14 (white solid, 72mg, 56% yield):1H NMR(300MHz,C5D5N)δ5.46-5.38(m,1H),4.90-4.81(m,1H),4.23-4.03(m,2H),3.92-3.73(m,2H),3.28-3.11(m,2H),1.27(s,3H),1.25(s,3H),1.07(s,3H),0.98(s,6H),0.94(s,6H).ESI-MS:m/z560.5[M-H]-。
example 15
12-ene-3 beta-acetoxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (Compound B-2)
Figure BDA0002381652130000192
Compound I-1(5g, 10mmol) from example 1 was dissolved in anhydrous dichloromethane (80mL), and oxalyl chloride (1.7mL, 20mmol) and N, N-dimethylformamide (5 drops) were slowly added dropwise with stirring and reacted at room temperature for 5 hours. After completion of the TLC detection reaction, the solvent was distilled off under reduced pressure to obtain Compound I-2 (yellow solid, 5.17g, yield 100%).
Compound I-2(5.17g, 10mmol) was dissolved in anhydrous dichloromethane (80mL), 3-bromopropylamine hydrobromide (4.4g, 20mmol) was added, triethylamine (5.5mL, 40mmol) was dissolved in anhydrous dichloromethane (20mL), and a solution of triethylamine in dichloromethane was slowly added dropwise to the reaction solution using a constant pressure dropping funnel. Stir at room temperature overnight. After completion of the TLC detection reaction, the solvent was distilled off under reduced pressure, water (300mL) was added and extracted with ethyl acetate (300 mL. times.3), and the mixture was washed with saturated brine (300 mL. times.3), and the filtrate was concentrated and dried to obtain a crude compound I-3 which was used as it was in the next reaction.
The crude compound I-3 obtained in the previous step was dissolved in N, N-dimethylformamide (100mL), and potassium carbonate (2.7g, 20mml) was added thereto, followed by reaction with heating at 50 ℃ for 12 hours. After the reaction is finished, pouring the reaction liquid into 500mL of ice water, separating out white solid, carrying out suction filtration, and drying a filter cake. Recrystallization from methanol gave compound B-2 (white solid, 3.57g, 64% over two steps):1H NMR(300MHz,DMSO)δ5.27-5.14(m,1H),4.56-4.40(m,1H),4.20-3.96(m,2H),3.45-3.24(m,2H),2.89-2.74(m,1H),2.04(s,3H),1.12(s,3H),0.94(s,3H),0.92(s,3H),0.88(s,3H),0.87(s,3H),0.86(s,3H),0.81(s,3H).ESI-MS:m/z 538.5[M+H]+。
example 16
Olean-12-ene-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -3 beta-ol (Compound B-1)
Figure BDA0002381652130000201
Dissolving compound B-2(3.5g, 6.2mmol) in 50mL of methanol, adding potassium hydroxide (3.4g, 62mmol), heating to 50 ℃ and stirring for reaction, detecting completion of the reaction by TLC, after completion of the reaction, cooling to room temperature, adding 50mL of water, extracting with ethyl acetate (50mL × 3), washing with saturated brine (50mL × 3), drying over anhydrous sodium sulfate, concentrating under reduced pressure, and recrystallizing with methanol to obtain compound B-1 (white solid, 2.7g, yield 87%):1H NMR(300MHz,DMSO)δ5.29-5.12(m,1H),4.17-3.96(m,2H),3.42-3.29(m,2H),3.28-3.14(m,1H),2.90-2.74(m,1H),1.12(s,3H),0.99(s,3H),0.91(s,6H),0.88(s,3H),0.81(s,3H),0.78(s,3H).ESI-MS:m/z 496.4[M+H]+. The single crystal diffraction of compound B-1 is shown in FIG. 1.
Example 17
12-ene-3 beta-propionyloxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (compound B-3)
Figure BDA0002381652130000211
Dissolving compound B-1(200mg, 0.40mmol) in pyridine (3mL), sequentially adding 4-dimethylaminopyridine (5mg, 0.04mmol) and propionic anhydride (133uL, 1mmol), stirring the reaction at room temperature, detecting completion of the reaction by TLC, adding 1N hydrochloric acid (5mL), extracting with ethyl acetate (5mL × 3), washing with saturated saline (5mL × 3), drying over anhydrous sodium sulfate, concentrating under reduced pressure, and subjecting to silica gel column chromatography (petroleum ether: ethyl acetate ═ 10:1) to obtain compound B-3 (white solid, 166mg, yield 75%):1H NMR(300MHz,CDCl3)δ5.24-5.16(m,1H),4.55-4.44(m,1H),4.17-4.00(m,2H),3.33(t,J＝9.9Hz,2H),2.87-2.75(m,1H),2.32(q,J＝6.6Hz,2H),0.94(s,3H),0.91(s,3H),0.88(s,3H),0.86(s,9H),0.81(s,3H).ESI-MS:m/z 552.6[M+H]+。
example 18
12-ene-3 β -butyryloxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (Compound B-4)
Figure BDA0002381652130000212
Referring to the procedure of example 17, substituting propionic anhydride for succinic anhydride produced compound B-4:1H NMR(300MHz,CDCl3)δ5.24-5.16(m,1H),4.55-4.44(m,1H),4.17-4.00(m,2H),3.33(t,J＝9.9Hz,2H),2.87-2.75(m,1H),2.32(q,J＝6.6Hz,2H),0.94(s,3H),0.91(s,3H),0.88(s,3H),0.86(s,9H),0.81(s,3H).ESI-MS:m/z 566.7[M+H]+。
example 19
12-ene-3 beta-valeryloxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (Compound B-5)
Figure BDA0002381652130000221
Referring to the procedure of example 17, substituting propionic anhydride for pentanoic anhydride, compound B-5 is prepared:1H NMR(300MHz,CDCl3)δ5.23-5.13(m,1H),4.55-4.41(m,1H),4.17-4.00(m,2H),3.39-3.27(m,2H),2.89-2.74(m,2H),2.29(t,J＝7.3Hz,2H),1.12(s,3H),0.93(s,3H),0.91(s,3H),0.87(s,3H),0.85(s,6H),0.80(s,3H).ESI-MS:m/z 580.5[M+H]+。
example 20
12-ene-3 beta- (4-fluorobenzoyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (compound B-6)
Figure BDA0002381652130000222
Compound B-1(200mg, 0.40mmol) was dissolved in dichloromethane (3mL), and N, N' -dicyclohexylcarbodiimide (247mg, 1.2mmol), 4-dimethylaminopyridine (48mg, 0.4mmol) and p-fluorobenzoic acid (122mg, 1 m) were added in this ordermol), stirring the reaction at room temperature. TLC after completion of the reaction was washed with water (5mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether: ethyl acetate ═ 10:1) to give compound B-6 (white solid, 186mg, yield 80%):1H NMR(300MHz,CDCl3)δ8.05(dd,J＝8.3,5.6Hz,2H),7.10(t,J＝8.5Hz,2H),5.42-5.34(m,1H),4.78-4.65(m,1H),3.65-3.44(m,2H),3.27-2.98(m,2H),2.65-2.44(m,1H),1.19(s,3H),1.01(s,3H),0.99(s,3H),0.94(s,3H),0.91(s,6H),0.79(s,3H).ESI-MS:m/z 618.5[M+H]+。
example 21
Olean-12-en-3 β - (4-chlorobenzoyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) (Compound B-7)
Figure BDA0002381652130000231
Referring to the procedure of example 20, p-fluorobenzoic acid was substituted for p-chlorobenzoic acid to give compound B-7:1H NMR(300MHz,CDCl3)δ7.97(d,J＝8.4Hz,2H),7.41(d,J＝8.5Hz,2H),5.40(m,1H),4.82-4.61(m,1H),3.66-3.47(m,2H),3.35-3.06(m,2H),2.68-2.39(m,1H),1.19(s,3H),1.01(s,3H),0.99(s,3H),0.94(s,3H),0.92(s,6H),0.79(s,3H).ESI-MS:m/z 635.5[M+H]+。
example 22
12-ene-3 beta- (4-methylbenzoyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (compound B-8)
Figure BDA0002381652130000232
Referring to the procedure of example 20, p-fluorobenzoic acid was substituted for p-methylbenzoic acid to obtain compound B-8:1H NMR(300MHz,CDCl3)δ7.99(d,J＝8.7Hz,2H),6.92(d,J＝8.7Hz,2H),5.45-5.33(m,1H),4.80-4.57(m,1H),3.86(s,3H),3.64-3.43(m,2H),3.27-3.09(m,2H),2.57-2.38(m,2H),1.18(s,3H),1.01(s,3H),0.99(s,3H),0.94(s,3H),0.91(s,6H),0.79(s,3H).ESI-MS:m/z 614.4[M+H]+。
example 23
12-ene-3 beta- (4-methoxybenzoyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (compound B-9)
Figure BDA0002381652130000241
Referring to the procedure of example 20, p-fluorobenzoic acid was substituted for p-methoxybenzoic acid to give compound B-9:1H NMR(300MHz,CDCl3)δ8.01(d,J＝8.6Hz,2H),6.93(d,J＝8.7Hz,2H),5.45-5.37(m,1H),4.79-4.63(m,1H),3.87(s,3H),3.67-3.50(m,2H),3.29-3.12(m,2H),2.67-2.49(m,1H),1.20(s,3H),1.03(s,3H),1.01(s,3H),0.95(s,3H),0.93(s,6H),0.81(s,3H).ESI-MS:m/z 630.5[M+H]+。
example 24
12-ene-3 beta- (4-trifluoromethoxybenzoyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (compound B-10)
Figure BDA0002381652130000242
Referring to the procedure of example 20, p-fluorobenzoic acid was substituted for p-trifluoromethoxybenzoic acid to give compound B-10:1H NMR(300MHz,CDCl3)δ8.10(d,J＝8.7Hz,2H),7.32-7.25(m,2H),5.45-5.34(m,1H),4.83-4.64(m,1H),3.69-3.43(m,2H),3.26-3.03(m,2H),2.66-2.43(m,1H),1.20(s,3H),1.03(s,3H),1.01(s,3H),0.96(s,3H),0.93(s,6H),0.81(s,3H).ESI-MS:m/z 684.4[M+H]+。
example 25
12-ene-3 beta- (4-methoxylbenzoyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (Compound B-11)
Figure BDA0002381652130000251
Method according to example 20Replacing p-fluorobenzoic acid with p-methoxylbenzoic acid to obtain a compound B-11:1H NMR(300MHz,CDCl3)δ8.26-7.96(m,4H),5.46-5.39(m,1H),4.83-4.69(m,1H),3.95(s,3H),3.66-3.56(m,2H),3.42-3.25(m,2H),2.66-2.49(m,1H),1.18(s,3H),1.01(s,3H),0.99(s,3H),0.94(s,3H),0.93(s,6H),0.81(s,3H).ESI-MS:m/z 658.4[M+H]+。
example 26
12-ene-3 beta- (3-pyridinoformyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (compound B-12)
Figure BDA0002381652130000252
Referring to the procedure of example 20, substituting p-fluorobenzoic acid for nicotinic acid gives compound B-12:1H NMR(300MHz,CDCl3)δ9.25(s,1H),8.78(d,J＝3.7Hz,1H),8.31(d,J＝7.9Hz,1H),7.40(dd,J＝7.7,4.9Hz,1H),5.27-5.13(m,1H),4.90-4.68(m,1H),4.26-3.95(m,2H),3.42-3.26(m,2H),2.98-2.77(m,1H),1.17(s,3H),1.04(s,3H),1.01(s,3H),0.97(s,3H),0.94(s,3H),0.91(s,3H),0.85(s,3H).ESI-MS:m/z 601.5[M+H]+。
example 27
12-ene-3 beta- (2-carboxybenzoyl) oxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (compound B-13)
Figure BDA0002381652130000253
Figure BDA0002381652130000261
Compound B-1(200mg, 0.39mmol) was dissolved in methylene chloride (4mL), and N, N' -dicyclohexylcarbodiimide (247mg, 1.2mmol), 4-dimethylaminopyridine (48mg, 0.4mmol) and monobenzyl phthalate (205mg, 0.8mmol) were added in this order, and the reaction was stirred at room temperature. After completion of the TLC detection reaction, it was washed with water (5mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether: ethyl acetate ═ 10:1) to obtain compound I-6 (white solid, 208mg, yield 73%).
Compound I-6(200mg, 0.272mmol) was dissolved in DCM (4mL), 10% palladium on carbon (10mg) was added, and the reaction was stirred under hydrogen atmosphere at room temperature overnight. After completion of the TLC detection reaction, celite was filtered and the filtrate was concentrated to give Compound B-15 (white solid, 164mg, 92% yield):1H NMR(300MHz,CDCl3)δ8.58(s,1H),7.78(d,J＝7.0Hz,1H),7.61(d,J＝6.6Hz,1H),7.50-7.37(m,2H),5.33-5.18(m,1H),4.80-4.64(m,1H),4.31-4.18(m,2H),3.75-3.38(m,2H),2.95-2.72(m,1H),1.15(s,3H),0.98(s,3H),0.94(s,3H),0.91(s,3H),0.90(s,3H),0.89(s,3H),0.79(s,3H).ESI-MS:m/z 642.4[M-H]-。
example 28
12-ene-3 beta-phosphoxy-28- (5, 6-dihydro-4H-1, 3-oxazin-2-yl) -oleanane (Compound B-14)
Figure BDA0002381652130000262
Dissolving compound B-1(200mg, 0.40mmol) in dichloromethane (8mL), first adding 1H-tetrazole (109 μ L, 1.2mmol), stirring at room temperature for 10 minutes, then adding dibenzyl N, N-diisopropylphosphoramidite (153 μ L, 0.45mmol), stirring at room temperature for 4 hours under nitrogen atmosphere, after TLC detection reaction is complete, adding m-chloroperoxybenzoic acid (157mg, 0.9mmol), stirring at room temperature for 4 hours, after TLC detection reaction is complete, adding saturated ammonium chloride solution (8mL), quenching, washing with saturated sodium bicarbonate solution (5mL × 2), drying over anhydrous sodium sulfate, filtering, concentrating the filtrate, and purifying by silica gel column chromatography (petroleum ether: ethyl acetate ═ 15: 1) to obtain compound I-7 (white solid, 275mg, yield 80%).
Compound I-7(200mg, 0.26mmol) was dissolved in a mixed solvent of tetrahydrofuran (2mL) and methanol (2mL), 10% palladium on carbon (10mg) was added, and the reaction was stirred under hydrogen atmosphere at room temperature overnight. After completion of TLC detection, celite was filtered, the filtrate was concentrated and slurried with ethyl acetate to give Compound B-14 (white solid, 61mg, 40% yield)：1H NMR(300MHz,C5D5N)δ5.38-5.31(m,1H),4.89-4.77(m,1H),4.11-3.90(m,2H),3.48-3.30(m,2H),3.23-3.12(m,1H),1.23(s,6H),1.04(s,3H),0.97(s,6H),0.94(s,3H),0.90(s,3H).ESI-MS:m/z 574.5[M-H]-。
Example 29
Evaluation of Activity of Compounds on Huh-7 cell AMPK agonism
The Western Blot method is adopted to detect the agonistic activity of the compound on Huh-7 cell AMPK.
1. Cell line: huh-7 cells (human hepatoma cells, purchased from the stem cell bank of Chinese academy of sciences) were cultured in DMEM complete medium (containing 10% fetal bovine serum and 1% streptomycin/penicillin) containing 5% CO at 37 deg.C2Cultured in a cell culture box.
2. Antibody: anti-AMPK (Cell Signaling Technology 2532S); anti-pAMPK (Thr172, Cell Signaling Technology 2535S); gapdh (arigobio), HRP-labeled goat anti-rabbit IgG secondary antibody, HRP-labeled goat anti-mouse IgG secondary antibody (bi yun day).
3. Western Blot experiment: the effect of the compounds on AMPK phosphorylation levels in Huh-7 cells was examined.
The experiment was carried out using cells with a viable cell ratio of 90% or more. In 12-well plates, Huh-7 cells were plated at 20 ten thousand per well. At 37 deg.C, contains 5% CO2The cells were cultured in the incubator for 24 hours and adhered to the wall. Test compounds were administered under complete medium conditions, with compound final concentrations set at 10 μ M for 12 hours, and AICAR (200 μ M), oleanolic acid (10 μ M) were used as positive control compounds. Proteins were subsequently extracted for Western Blot detection. The method comprises the following specific steps:
protein sample preparation: discarding the original culture solution, washing 3 times with 1 XPBS, discarding PBS, adding 100 μ l RIPA buffer (1 XPBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, PMSF, etc.) per well, incubating on ice for 15min, scraping cells with a cell scraper, sucking into a new 1.5ml EP tube, 4 ℃, 12000g, centrifuging for 15min, transferring the supernatant to a new 1.5ml EP tube, placing on ice, adding 1/5 volume of 6 × loading buffer, heating in a 95 ℃ metal bath for 10min, centrifuging for 1min, and freezing to-20 ℃ for use.
Protein quantification: the protein sample was diluted 20-fold, and 20. mu.l of the diluted protein sample and 200. mu.l of BCA (solution A: solution B ═ 5: 1) reagent were sequentially added to a 96-well plate, incubated at 37 ℃ for 30min, and the OD value was measured at a wavelength of 562nm on a microplate reader, and the protein concentration was calculated from the standard curve.
Electrophoresis: SDS-PAGE gel is poured, the concentration of the separation gel is 10 percent, and the concentration of the concentrated gel is 4 percent. The protein samples were previously heated in a metal bath at 95 ℃ for 4min and then centrifuged for 1min, and 30. mu.g of total protein was applied to each sample, and the samples were individually applied by a microsyringe. The power supply is connected (note that the positive electrode and the negative electrode are connected), constant voltage electrophoresis is carried out at 60V at the beginning, and when the protein sample enters the separation gel, the voltage is adjusted to 100V to continue the constant voltage electrophoresis. When bromophenol blue reaches the bottom of the separation gel, electrophoresis is terminated according to the separation condition of protein marker.
Film transfer: the gel after electrophoresis was gently removed, an unnecessary portion was cut off, and the necessary gel was immersed in a Transfer buffer. PVDF membrane of the same size as the gel was prepared, and the PVDF membrane was soaked with methanol for 1min before use, transferred to a Transfer buffer, and simultaneously the filter paper was soaked in the Transfer buffer. And sequentially paving sponge, filter paper, glue, a PVDF (polyvinylidene fluoride) membrane, filter paper and sponge on an electrode plate of the transfer printing instrument cathode. Air bubbles are avoided between each layer. And switching on a power supply, and transferring for 2.5h by a 200mA constant-current ice bath.
Antibody hybridization: after completion of the membrane transfer, the PVDF membrane was taken out and washed 1 time with l.times.TBST, placed in a blocking solution (5% BSA solution prepared with 1. times.TBS containing 0.1% Tween 20) prepared in advance, and blocked at room temperature for 1 hour. Primary antibody was incubated overnight at 4 ℃. The following day (after 12 h), wash 3 times with 1 × TBST for 10min each. And (3) secondary antibody incubation: incubate with 5% BSA diluted secondary antibody (1: 10000) at room temperature for 1h, wash 3 times with 1 × TBST, 10min each. Excess liquid on PVDF membrane was aspirated, spread on an exposure plate, and equal volume of mixed ECL kit liquid Tanon was addedTMHigh-sig ECL Western Blotting Peroxide Buffer and TanonTMHigh-sig ECL Western Blotting lumineol/Enhancer Solution, using Tanon chemiluminescence imager, ECL development, and collecting immunoreaction zone.
4. The experimental results are as follows: after the Western Blot experiment result is subjected to gray scale scanning, the p-AMPK/AMPK ratio of negative control DMSO is defined as 1, the p-AMPK/AMPK ratio of the synthesized test compound is a relative ratio of a negative control group, the larger the value is, the stronger the AMPK agonistic activity of the compound is, and the activity data result is shown in Table 1.
TABLE 1 AMPK agonistic activity of the compounds (positive control AICAR concentration 200. mu.M; oleanolic acid, test compound concentration 10. mu.M)
Figure BDA0002381652130000281
Figure BDA0002381652130000291
Figure BDA0002381652130000301
Figure BDA0002381652130000311
As shown in table 1 and the experimental results of fig. 2, the novel oleanolic acid derivatives provided by the present invention have significant AMPK agonistic activity at a concentration of 10 μ M. For example, compounds A-1, A-2, A-3, A-4, A-5, A-12, B-5, B-12, B-13, B-14 are potent AMPK agonists with activities significantly better than 200 μ M AICAR and significantly better than oleanolic acid, especially A-1, A3 and B14. The above experimental results show that the compound of the present invention has significant agonistic activity on AMPK, and thus can be used to prepare AMPK agonists having activity of enhancing AMPK phosphorylation level, and further can be used to prepare drugs for preventing or treating AMPK-mediated diseases. Other compounds not listed in the examples of the present invention and methods for synthesizing the same can be found in the above examples, and also have significant agonistic activity against AMPK.
Example 30
Tablet formulation
Compound B-14 obtained in example 28 or the compound of the other examples (50g), hydroxypropylmethylcellulose E (150g), starch (200g), povidone K30, and magnesium stearate (1g) were mixed, granulated, and tabletted.
In addition, the compounds prepared in examples 1 to 28 can be prepared into capsules, powders, granules, pills, injections, syrups, oral liquids, inhalants, ointments, suppositories, patches and the like by adding different pharmaceutical excipients according to the conventional preparation method of pharmacopoeia 2015 edition.

Claims (10)

1. Oleanolic acid derivatives represented by the following formula I or formula II:
Figure FDA0003238051360000011
r is H,
Figure FDA0003238051360000012
RaCO-or PO3H2；
R1Is H;
Rais C1-C5An alkyl group.
2. The derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein the derivative or the pharmaceutically acceptable salt thereof is selected from the following compounds:
Figure FDA0003238051360000013
Figure FDA0003238051360000021
Figure FDA0003238051360000031
3. an oleanolic acid derivative or a pharmaceutically acceptable salt thereof, wherein said derivative or said pharmaceutically acceptable salt thereof is selected from the group consisting of:
Figure FDA0003238051360000041
Figure FDA0003238051360000051
Figure FDA0003238051360000061
4. use of a derivative as claimed in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, in the manufacture of an AMPK agonist having activity in enhancing the phosphorylation level of AMPK.
5. Use of a derivative according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of AMPK mediated diseases.
6. The use according to claim 5, wherein the AMPK-mediated disease comprises a metabolic disease, a cardiovascular disease, a cerebrovascular disease, an inflammatory disease, an autoimmune disease, an organ fibrosis disease, a neurodegenerative disease, a secondary disease caused by pathogen infection, a mitochondrial dysfunction or disorder disease, or a tumor.
7. The use according to claim 5, wherein the AMPK-mediated disease comprises insulin resistance, metabolic syndrome, type 1 or type 2 diabetes, hyperlipidemia, obesity, atherosclerosis, myocardial ischemia, myocardial infarction, cardiac arrhythmia, coronary heart disease, hypertension, heart failure, myocardial hypertrophy, myocarditis, diabetic complications, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcoholic fatty liver disease, liver cirrhosis, gout, stroke, cerebral infarction, pneumonia, asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, bronchiolitis obliterans, idiopathic pulmonary fibrosis, cystic fibrosis lung disease, allergic rhinitis, inflammatory bowel disease, polycystic kidney disease, polycystic ovary syndrome, Behcet's disease, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis, osteoarthritis, synovitis, tendonitis, thromboangiitis obliterans, rheumatoid arthritis, polycystic kidney disease, hyperlipidemia, obesity, atherosclerosis, myocardial ischemia, myocardial infarction, chronic bronchitis, emphysema, pulmonary fibrosis, polycystic kidney disease, rheumatoid arthritis, osteoarthritis, synovitis, and rheumatoid arthritis, Phlebitis, intermittent claudication, keloid, psoriasis, ichthyosis, bullous pemphigoid, dermatitis, contact dermatitis, pancreatitis, chronic nephritis, cystitis, meningitis, gastritis, septicemia, pyoderma gangrenosum, uveitis, Parkinson's disease, Alzheimer's disease, alpha-synucleinopathy, depression, multiple sclerosis, amyotrophic lateral sclerosis, fibromyalgia syndrome, neuralgia, Down's syndrome, Hallervorden-Spanish disease, Huntington's chorea, Wilson's disease, myasthenia, myoclonus, exercise intolerance, Kanes-Seir syndrome, chronic fatigue syndrome, Lei's syndrome, mitochondrial myopathy-encephalopathy-lactacidemia, stroke syndrome, stroke-like seizures, Duchenne's muscular dystrophy, conchal muscular dystrophy, Friedrich's ataxia or tumors.
8. A pharmaceutical composition having an activity of enhancing phosphorylation level of AMPK, comprising the derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 2 as an active ingredient and a pharmaceutically acceptable excipient.
9. A pharmaceutical composition for preventing or treating AMPK-mediated diseases, comprising the derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2 as an active ingredient and a pharmaceutically acceptable adjuvant.
10. The pharmaceutical composition according to claim 8 or 9, wherein the pharmaceutical composition is a capsule, powder, tablet, granule, pill, injection, syrup, oral liquid, inhalant, ointment, suppository or patch.
CN202010084760.0A 2020-02-10 2020-02-10 Oleanolic acid derivative and medical application thereof Active CN111205346B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010084760.0A CN111205346B (en) 2020-02-10 2020-02-10 Oleanolic acid derivative and medical application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010084760.0A CN111205346B (en) 2020-02-10 2020-02-10 Oleanolic acid derivative and medical application thereof

Publications (2)

Publication Number Publication Date
CN111205346A CN111205346A (en) 2020-05-29
CN111205346B true CN111205346B (en) 2022-01-28

Family

ID=70782717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010084760.0A Active CN111205346B (en) 2020-02-10 2020-02-10 Oleanolic acid derivative and medical application thereof

Country Status (1)

Country Link
CN (1) CN111205346B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117567544A (en) * 2021-04-27 2024-02-20 中国医学科学院药物研究所 Application of pentacyclic triterpene compounds with alpha, beta-unsaturated ketone structures in preventing and treating neurodegenerative diseases
CN115806580A (en) * 2021-09-14 2023-03-17 中国医学科学院药物研究所 12-O-fatty acid ester oleanolic acid compound and preparation method and application thereof
CN113817017B (en) * 2021-11-19 2022-03-29 华南理工大学 Oleanolic acid oxime ester derivative and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101496806A (en) * 2008-01-31 2009-08-05 中国科学院上海药物研究所 Use of compound extracted from bitter melon in preparing medicament for preventing and treating diabetes and fat disease
CN110200981A (en) * 2019-06-06 2019-09-06 中国药科大学 The medical usage and its pharmaceutical composition of pentacyclic triterpene saponin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101713140B1 (en) * 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
CN102066398B (en) * 2008-04-18 2014-09-10 里亚塔医药公司 Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
CN105998032B (en) * 2016-06-02 2019-12-03 贵州医科大学 The application of oleanolic acid derivate and its pharmaceutical composition in drug

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101496806A (en) * 2008-01-31 2009-08-05 中国科学院上海药物研究所 Use of compound extracted from bitter melon in preparing medicament for preventing and treating diabetes and fat disease
CN110200981A (en) * 2019-06-06 2019-09-06 中国药科大学 The medical usage and its pharmaceutical composition of pentacyclic triterpene saponin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Oleanolic acid induces autophagic death in human gastric cancer cells in vitro and in vivo;H. Nie et al.;《Cell Biol Int》;20161231;第40卷;第770-778页 *
Oleanolic Acid Induces Metabolic Adaptation in Cancer Cells by Activating the AMP-Activated Protein Kinase Pathway;Jia Liu等;《Journal of Agricultural and Food Chemistry》;20140523;第62卷;第5528-5537页 *
Protective effect of triterpenes against diabetes-induced β-cell damage_ An overview of in vitro and in vivo studies;Sihle E. Mabhida等;《Pharmacological Research》;20181231;第137卷;第179-192页 *

Also Published As

Publication number Publication date
CN111205346A (en) 2020-05-29

Similar Documents

Publication Publication Date Title
CN111205346B (en) Oleanolic acid derivative and medical application thereof
AU2017213032B2 (en) Steroid derivative FXR agonist
JP2022174114A (en) Alk protein decomposer and use thereof in cancer therapy
CA2712614C (en) Combination therapy comprising sglt inhibitors and dpp4 inhibitors
EP0609437B1 (en) Novel sphingoglycolipid and use thereof
TWI584808B (en) Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
EP3532069A1 (en) Antiviral aryl-amide phosphodiamide compounds
CN112142818B (en) Derivatives of oleanolic acid and delta-oleanolic acid and medical application thereof
KR20140016428A (en) Lupeol-type triterpene derivatives as antivirals
WO2018208727A1 (en) Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
KR102506149B1 (en) Chemical compounds and use thereof for improving muscular quality
CN112110978B (en) Delta-oleanolic acid saponin compound and medical application thereof
EP3883946A1 (en) Alpha-d-galactoside inhibitors of galectins
WO2016084790A1 (en) Hydronaphthoquinoline derivative
EP2910561A1 (en) Sialic acid derivatives
HRP20010529A2 (en) 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors
JP2015529254A (en) Novel GABAA agonists and methods of use for controlling airway hypersensitivity and inflammation in asthma
CN113727989B (en) Novel triterpene derivatives as HIV inhibitors
WO2022211627A1 (en) Inhibitors of nicotinamide n-methyl transferase (nnmt)
CN112694514B (en) Pentacyclic triterpenoid TGR5 receptor agonist, and preparation method and application thereof
WO2021053158A1 (en) Novel histone methyltransferase inhibitors
KR20220164216A (en) Novel ergostenol derivatives, and uses thereof
WO2017100153A1 (en) Therapeutic compounds
EA038580B1 (en) Steroid derivative fxr agonist
CN107880006B (en) The compound as SGLT-2 inhibitor containing cyclohexane structure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant